Cosimo Prantera

Summary

Country: Italy

Publications

  1. ncbi A new oral delivery system for 5-ASA: preliminary clinical findings for MMx
    Cosimo Prantera
    Department of Gastroenterology, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
    Inflamm Bowel Dis 11:421-7. 2005
  2. ncbi Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease
    Cosimo Prantera
    Gastroenterology Unit, San Camillo Forlanini Hospital, Rome, Italy
    Gastroenterology 142:473-481.e4. 2012
  3. ncbi Beclomethasone dipropionate in Crohn's ileitis: a randomised, double-blind trial
    Cosimo Prantera
    Azienda Ospedaliera San Camillo Forlanini, Rome, Italy
    Dig Liver Dis 43:459-64. 2011
  4. ncbi Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol
    C Prantera
    Department of Gastroenterology, Azienda Osp S Camillo Forlanini, Rome, Italy
    Aliment Pharmacol Ther 30:908-18. 2009
  5. ncbi Mycobacteria and Crohn's disease: the endless story
    C Prantera
    Gastrointestinal Unit, San Camillo-Forlanini Hospital, Rome, Italy
    Dig Liver Dis 39:452-4. 2007
  6. ncbi Probiotics for Crohn's disease: what have we learned?
    C Prantera
    Division of Gastroenterology, Azienda Ospedaliera S Camillo-Forlanini, 00149 Roma, Italia
    Gut 55:757-9. 2006
  7. ncbi Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin
    C Prantera
    Operative Unit of Gastroenterology, St Camillo Forlanini Hospital, Rome, Italy
    Aliment Pharmacol Ther 23:1117-25. 2006
  8. ncbi Probiotics and Crohn's disease
    C Prantera
    Division of Gastroenterology, S Camillo Forlanini Hospital, Rome, Italy
    Dig Liver Dis 34:S66-7. 2002
  9. ncbi Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG
    C Prantera
    Division of Gastroenterology, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
    Gut 51:405-9. 2002
  10. ncbi Antibiotics and probiotics in inflammatory bowel disease: why, when, and how
    Cosimo Prantera
    Azienda Ospedaliera San Camillo Forlanini, Rome, Italy
    Curr Opin Gastroenterol 25:329-33. 2009

Detail Information

Publications13

  1. ncbi A new oral delivery system for 5-ASA: preliminary clinical findings for MMx
    Cosimo Prantera
    Department of Gastroenterology, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
    Inflamm Bowel Dis 11:421-7. 2005
    ..This study had 2 objectives: (1) to evaluate the therapeutic response to MMx in patients with active left-sided disease and (2) to gain additional insights as to how the therapy would compare with topical 5-ASA...
  2. ncbi Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease
    Cosimo Prantera
    Gastroenterology Unit, San Camillo Forlanini Hospital, Rome, Italy
    Gastroenterology 142:473-481.e4. 2012
    ..We performed a clinical phase 2 trial to determine whether a gastroresistant formulation of rifaximin (extended intestinal release [EIR]) induced remission in patients with moderately active CD...
  3. ncbi Beclomethasone dipropionate in Crohn's ileitis: a randomised, double-blind trial
    Cosimo Prantera
    Azienda Ospedaliera San Camillo Forlanini, Rome, Italy
    Dig Liver Dis 43:459-64. 2011
    ..Steroids, the mainstay of Crohn's disease treatment, have been associated with systemic side effects...
  4. ncbi Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol
    C Prantera
    Department of Gastroenterology, Azienda Osp S Camillo Forlanini, Rome, Italy
    Aliment Pharmacol Ther 30:908-18. 2009
    ..5-ASA-MMX (1.2 g/tablet) is a 5-aminosalicylic acid formulation, designed for once-daily dosing in the treatment of ulcerative colitis...
  5. ncbi Mycobacteria and Crohn's disease: the endless story
    C Prantera
    Gastrointestinal Unit, San Camillo-Forlanini Hospital, Rome, Italy
    Dig Liver Dis 39:452-4. 2007
  6. ncbi Probiotics for Crohn's disease: what have we learned?
    C Prantera
    Division of Gastroenterology, Azienda Ospedaliera S Camillo-Forlanini, 00149 Roma, Italia
    Gut 55:757-9. 2006
  7. ncbi Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin
    C Prantera
    Operative Unit of Gastroenterology, St Camillo Forlanini Hospital, Rome, Italy
    Aliment Pharmacol Ther 23:1117-25. 2006
    ..Clinicians often employ antibiotics in Crohn's disease. Rifaximin is active against bacteria frequently found in the intestinal mucosa of Crohn's disease patients...
  8. ncbi Probiotics and Crohn's disease
    C Prantera
    Division of Gastroenterology, S Camillo Forlanini Hospital, Rome, Italy
    Dig Liver Dis 34:S66-7. 2002
    ..Forty-five patients have been randomised to receive Lactobacillus rhamnosus strain GG or placebo for 12 months. The results have shown no differences in endoscopic and clinical remission between the two groups...
  9. ncbi Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG
    C Prantera
    Division of Gastroenterology, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
    Gut 51:405-9. 2002
    ..The aim of this randomised placebo controlled study was to determine if Lactobacillus GG, given by mouth for one year, could prevent Crohn's recurrent lesions after surgery or to reduce their severity...
  10. ncbi Antibiotics and probiotics in inflammatory bowel disease: why, when, and how
    Cosimo Prantera
    Azienda Ospedaliera San Camillo Forlanini, Rome, Italy
    Curr Opin Gastroenterol 25:329-33. 2009
    ..To summarize recent evidence on the role of intestinal bacteria in inflammatory bowel diseases, and of antibiotics and probiotics in their treatment. The implications connected with the use of antibiotics are also examined...
  11. ncbi Delayed-release Multi Matrix System (MMX) mesalazine in ulcerative colitis: a viewpoint by Cosimo Prantera
    Cosimo Prantera
    Gastroenterology Unit, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy
    Drugs 67:2643-4. 2007
  12. ncbi Does stapled functional end-to-end anastomosis affect recurrence of Crohn's disease after ileocolonic resection?
    Roberto Tersigni
    Department of Surgical Sciences, General Surgery 1, San Camillo Hospital, Rome, Italy
    Hepatogastroenterology 50:1422-5. 2003
    ..These observations need further investigation with randomized controlled trials, to compare the two different anastomotic procedures...
  13. ncbi Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use
    Silvio Danese
    Inflamm Bowel Dis 14:1168-70. 2008